[Federal Register: February 10, 2003 (Volume 68, Number 27)]
[Notices]
[Page 6750]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10fe03-88]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-03-42]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call the CDC Reports
Clearance Officer on (404) 498-1210.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Send comments to Anne O'Connor, CDC
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24,
Atlanta, GA 30333. Written comments should be received within 60 days
of this notice.
Proposed Project
Potential Reproductive and Neurological Effects of Exposure to
Acrylamide--NEW--The National Institute for Occupational Safety and
Health (NIOSH), Centers for Disease Control and Prevention (CDC).
The mission of the National Institute for Occupational Safety and
Health (NIOSH) is to promote safety and health at work for all people
through research and prevention. Consistent with this mission, NIOSH is
undertaking a study of the reproductive and neurobehavioral effects of
occupational exposure to acrylamide. Acrylamide workers and control
workers (n=100 per group) will be recruited from manufacturing, end-
user, and non-exposed settings. Exposure will be characterized by
acrylamide hemoglobin adduct and urinary metabolite levels, ambient
area, personal air, and dermal sampling. Reproductive effects will be
evaluated by examining semen quality, sperm DNA integrity, reproductive
hormone levels, and prostate specific antigen levels (PSA).
Neurobehavioral effects will be assessed using sensation-tactile,
postural stability, grooved pegboard, and simple reaction time tests.
Two questionnaires will be administered on one occasion. Questionnaire
information will be collected concurrently to augment test
interpretation, adjust for potential confounders and covariates during
regression analysis, correlate specific jobs and job activities with
exposure measurements, and for validation purposes. Findings from this
study will clarify if the adverse reproductive effects observed in
animal studies are also present in acrylamide-exposed workers, and if
preclinical neurobehavioral deficits are present at acrylamide doses
currently considered to be within safe limits. This study is scheduled
for implementation during 2003 and 2004. There are no costs to
respondents.
----------------------------------------------------------------------------------------------------------------
Number of Average burden/
Survey questionnaires Number of responses/ response (in Total burden
respondents respondent hrs.) (in hrs.)
----------------------------------------------------------------------------------------------------------------
Medical & Reproductive History Questionnaire..... 200 1 13/60 43
Occupational History Questionnaire............... 200 1 34/60 113
Non-participant Questionnaire.................... 50 1 2/60 2
==================================================
----------------------------------------------------------------------------------------------------------------
Dated: February 4, 2003.
Thomas Bartenfeld,
Acting Associate Director for Policy, Planning and Evaluation, Centers
for Disease Control and Prevention.
[FR Doc. 03-3128 Filed 2-7-03; 8:45 am]
BILLING CODE 4163-18-P